ANGLE PLC (LON:AGL, OTCQX:ANPCY) has welcomed new research that potentially supports the use of the company’s breakthrough cancer detection system as an alternative to biopsies in men with suspected prostate cancer.
The team at the Bart's Cancer Institute at Queen Mary University will present their full findings at the National Cancer Research Institute next week.
What they found was ANGLE’s Parsortix device was able to capture a very specific subset of circulating tumour cells from prostate cancer patient blood samples.
These cells, which cannot be captured by traditional systems, are linked to the spread of the disease.
It means Parsortix could potentially be used gauge at what stage and how severe the prostate cancer is.
Andrew Newland, chief executive and the med-tech company’s founder, said: "This is a significant milestone, which further supports the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue.”
Currently the removal of tissue is standard for men with suspected prostate cancer - yet 75% to 80% of them do not have the disease. It means they risk serious complications.
“Aside from being non-invasive, Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients,” said Newland.
“We look forward to our continued work with Barts to progress the use of Parsortix in prostate cancer."